Table of Contents
Kenneth Frazier, one of America’s prominent Black executives – has witnessed a significant increase in the market value of his stake in Merck & Co. – driven by the recent rise in the share price of the American multinational pharmaceutical company.
Formerly serving as the executive chairman and CEO of Merck & Co. Frazier has seen his stake in the New-Jersey-based pharmaceutical giant increase by $11.23 million since the year began, reflecting heightened investor interest in the company.
Frazier, who led Merck through a successful decade as CEO, received a total compensation package of $8.5 million from the U.S. pharmaceutical company in 2022 — marking a 78.6-percent decline from the previous year’s salary of $15.2 million.
Merck & Co. sees a 14.6-percent increase in share price, market cap surpasses $315 billion
Founded in 1891, Merck & Co., Inc. is a healthcare company based in New Jersey. It focuses on providing health solutions through prescription medicines, vaccines, biological therapies, animal health, and consumer care products. The company operates in three segments: Pharmaceutical, Animal Health, and Other.
Year-to-date, Merck & Co’s shares on the New York Stock Exchange have risen by 14.6 percent, climbing from $109.02 on Jan. 1 to $124.94 as of the current date. This positive trend has propelled the company’s market capitalization above $315 billion, delivering significant gains to its shareholders, including Frazier.
Frazier’s stake in Merck & Co. soars above $88 million amid recent share price surge
Frazier, who ranks as one of America’s top Black executives, holds a minority stake of 0.028-percent stake in Merck & Co., equivalent to 705,220 shares with a present value of $88.11 million.
According to data tracked by Billionaires.Africa reveals that the market value of Frazier’s stake in Merck & Co. has risen by $11.23 million since the beginning of the year, moving from $76.88 million on Jan. 1 to $88.11 at the time of drafting this report.
The recent upswing in Merck & Co. share price underscores Frazier’s strategic leadership and the company’s commitment to innovation and sustainable healthcare solutions, which continue to attract investors.
The intelligence satisfies curiosity. The paid briefings satisfy strategy.
Every Monday, Elite subscribers receive an Investor Memo breaking down the deal, the structure and the positioning behind the week's most consequential African wealth story - the kind of analysis that doesn't appear anywhere else.
Twice a month, a Wealth Intelligence brief profiles a single billionaire's holdings, cash flows and expansion pipeline in detail no public source matches.
→ Executive ($25/mo): Daily newsletter + Deep-Dive Reports
→ Elite ($75/mo): Everything above + Investor Memos + Wealth Intelligence + Quarterly Analyst Briefings
Subscribe now
